Alexandra M. Stevens

Hematology | Oncology
6701 Fannin St
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications

Disrupting a Convergent Acetylation Circuit Collapses Leukemic Identity Across AML Subtypes.

Disrupting a Convergent Acetylation Circuit Collapses Leukemic Identity Across AML Subtypes.

Journal: bioRxiv : the preprint server for biology
Published: July 29, 2026

Real-world experience with IDH inhibitors in pediatric patients with IDH1- and IDH2-mutated acute myeloid leukemia and myelodysplastic syndrome.

Real-world experience with IDH inhibitors in pediatric patients with IDH1- and IDH2-mutated acute myeloid leukemia and myelodysplastic syndrome.

Journal: Haematologica
Published: May 12, 2026

Pediatric acute myeloid leukemia tumor composition predicts patient outcomes at diagnosis and reveals mechanisms of resistance to chemotherapy.

Pediatric acute myeloid leukemia tumor composition predicts patient outcomes at diagnosis and reveals mechanisms of resistance to chemotherapy.

Journal: Research square
Published: February 06, 2026

Pediatric acute myeloid leukemia tumor composition predicts patient outcomes at diagnosis and reveals mechanisms of resistance to chemotherapy.

Pediatric acute myeloid leukemia tumor composition predicts patient outcomes at diagnosis and reveals mechanisms of resistance to chemotherapy.

Journal: Research square
Published: February 06, 2026

Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Prediction in Pediatric AML.

Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Prediction in Pediatric AML.

Journal: bioRxiv : the preprint server for biology
Published: November 19, 2025

PROTAC-mediated targeting of IKKβ and NR4A1 for AML therapy.

PROTAC-mediated targeting of IKKβ and NR4A1 for AML therapy.

Journal: Oncogene
Published: October 23, 2025

Dual Targeting of IKKβ and NR4A1 for AML Therapy.

Dual Targeting of IKKβ and NR4A1 for AML Therapy.

Journal: bioRxiv : the preprint server for biology
Published: October 03, 2025

Pediatric Non-Down Syndrome Acute Megakaryoblastic Leukemia Patients Have Dismal Outcomes Irrespective of Allogeneic Hematopoietic Stem Cell Transplant: A Single-Center Experience.

Pediatric Non-Down Syndrome Acute Megakaryoblastic Leukemia Patients Have Dismal Outcomes Irrespective of Allogeneic Hematopoietic Stem Cell Transplant: A Single-Center Experience.

Journal: Cancers
Published: October 02, 2025

Mesothelin promotes acute myeloid leukemia progression through LYN-dependent signaling.

Mesothelin promotes acute myeloid leukemia progression through LYN-dependent signaling.

Journal: The Journal of biological chemistry
Published: September 04, 2025

On the road to improved therapies for therapy-related AML.

On the road to improved therapies for therapy-related AML.

Journal: Blood advances
Published: June 10, 2025

Targeting oncogenic FLT3 uncovers a ferroptosis vulnerability through selenocysteine recoding in acute myeloid leukaemia.

Targeting oncogenic FLT3 uncovers a ferroptosis vulnerability through selenocysteine recoding in acute myeloid leukaemia.

Journal: Nature cell biology
Published: May 16, 2025

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML.

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML.

Journal: Blood
Published: April 01, 2025
Showing 1-12 of 52

Last Updated: 09/26/2026